Merck & Co. to Acquire Terns Pharmaceuticals, Expands CML Pipeline with TERN-701

Merck & Co. has announced its acquisition of Terns Pharmaceuticals, strengthening its hematology portfolio with the addition of TERN-701, a novel oral therapy for Chronic Myeloid Leukemia (CML). The move underscores Merck’s strategic focus on advancing innovative treatments in oncology, particularly in hematologic malignancies with unmet clinical needs.

Advancing Next-Generation CML Treatment

TERN-701 is designed as a potent, selective BCR-ABL tyrosine kinase inhibitor, targeting resistance mutations commonly seen in CML patients. Its development aims to address limitations of existing therapies, including safety and tolerability challenges. The acquisition provides Merck with a promising late-stage candidate that could enhance treatment outcomes and expand options for patients with resistant or intolerant disease profiles.

Strategic Oncology Portfolio Expansion

This acquisition reflects Merck’s broader strategy to diversify and strengthen its oncology pipeline beyond immuno-oncology. By integrating Terns’ clinical assets and expertise, Merck aims to accelerate innovation in hematology and reinforce its competitive positioning in targeted cancer therapies. The deal also highlights ongoing industry consolidation as major players seek differentiated assets in precision oncology.